Chan, Kam Wa, et al. “Design of Clinical Trials in Integrative Medicine: The Issue of Personalization.” European Journal of Integrative Medicine, vol. 68, Elsevier BV, Apr. 2024, pp. 102365–65, https://doi.org/10.1016/j.eujim.2024.102365.

Chan, Kam Wa, et al. “Add-on Rehmannia-6–Based Chinese Medicine in Type 2 Diabetes and CKD.” Clinical Journal of the American Society of Nephrology, vol. 18, no. 9, Lippincott Williams & Wilkins, June 2023, pp. 1163–74, https://doi.org/10.2215/cjn.0000000000000199.

Cheang, Iokfai, et al. “The Traditional Chinese Medicine Qiliqiangxin in Heart Failure with Reduced Ejection Fraction: A Randomized, Double-Blind, Placebo-Controlled Trial.” Nature Medicine, vol. 30, no. 8, Nature Portfolio, Aug. 2024, pp. 2295–302, https://doi.org/10.1038/s41591-024-03169-2.

Yang, Yuejin, et al. “Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients with Acute Myocardial Infarction: The CTS-AMI Randomized Clinical Trial.” JAMA, vol. 330, no. 16, Oct. 2023, pp. 1534–45, https://doi.org/10.1001/jama.2023.19524.

Guo, Jianwen, et al. “Traditional Chinese Medicine FYTF-919 (Zhongfeng Xingnao Oral Prescription) for the Treatment of Acute Intracerebral Haemorrhage: A Multicentre, Randomised, Placebo-Controlled, Double-Blind, Clinical Trial.” The Lancet, Dec. 2024, pp. S0140-6736(24)02261X, https://doi.org/10.1016/S0140-6736(24)02261-X.

Zeng, Liling, et al. “Safety and Efficacy of Herbal Medicine for Acute Intracerebral Hemorrhage (CRRICH): A Multicentre Randomised Controlled Trial.” BMJ Open, vol. 9, no. 5, BMJ, May 2019, p. e024932, https://doi.org/10.1136/bmjopen-2018-024932.

Hu, C., et al. “Guizhi Fuling Capsule, an Ancient Chinese Formula, Attenuates Endometriosis in Rats via Induction of Apoptosis.” Climacteric, vol. 17, no. 4, Taylor & Francis, Feb. 2014, pp. 410–16, https://doi.org/10.3109/13697137.2013.876618.

Cai, Shengyu, et al. “Effect of Mulberry Leaf (Folium Mori) on Insulin Resistance via IRS-1/PI3K/Glut-4 Signalling Pathway in Type 2 Diabetes Mellitus Rats.” Pharmaceutical Biology, vol. 54, no. 11, May 2016, pp. 2685–91, https://doi.org/10.1080/13880209.2016.1178779.

Yan, Fenggen, et al. “The Formulae and Biologically Active Ingredients of Chinese Herbal Medicines for the Treatment of Atopic Dermatitis.” Biomedicine & Pharmacotherapy, vol. 127, July 2020, p. 110142, https://doi.org/10.1016/j.biopha.2020.110142.

Wang, Lung-Shuo, et al. “Clinical Patterns of Traditional Chinese Medicine for Ischemic Heart Disease Treatment: A Population-Based Cohort Study.” Medicina, vol. 58, no. 7, July 2022, p. 879, https://doi.org/10.3390/medicina58070879.

Xu, Feipeng, et al. “Recent Progress on the Application of Compound Formulas of Traditional Chinese Medicine in Clinical Trials and Basic Research in Vivo for Chronic Liver Disease.” Journal of Ethnopharmacology, vol. 321, Elsevier BV, Dec. 2023, pp. 117514–14, https://doi.org/10.1016/j.jep.2023.117514.

Li, Runfeng, et al. “Lianhuaqingwen Exerts Anti-Viral and Anti-Inflammatory Activity against Novel Coronavirus (SARS-CoV-2).” Pharmacological Research, vol. 156, June 2020, p. 104761, https://doi.org/10.1016/j.phrs.2020.104761.

Wang, Lan, et al. “Dissection of Mechanisms of Chinese Medicinal Formula Realgar-Indigo Naturalis as an Effective Treatment for Promyelocytic Leukemia.” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 12, Mar. 2008, pp. 4826–31, https://doi.org/10.1073/pnas.0712365105. Accessed 5 Mar. 2021.

Cheang, Iokfai, et al. “The Traditional Chinese Medicine Qiliqiangxin in Heart Failure with Reduced Ejection Fraction: A Randomized, Double-Blind, Placebo-Controlled Trial.” Nature Medicine, vol. 30, no. 8, Nature Portfolio, Aug. 2024, pp. 2295–302, https://doi.org/10.1038/s41591-024-03169-2.

Ji, Hangyu, et al. “Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities.” JAMA Internal Medicine, vol. 184, no. 7, American Medical Association, June 2024, pp. 727–27, https://doi.org/10.1001/jamainternmed.2024.1190.

Wu, Gaosong, et al. “Shexiang Baoxin Pill Enriches Lactobacillus to Regulate Purine Metabolism in Patients with Stable Coronary Artery Disease.” Phytomedicine, vol. 130, Elsevier BV, May 2024, pp. 155727–27, https://doi.org/10.1016/j.phymed.2024.155727.

 “Chinese Government in Push for Sustainable Traditional Medicine Resources.” Nature.com, Nature, 2020, www.nature.com/articles/d42473-020-00001-6.

Zuntini, Alexandre R., et al. “Phylogenomics and the Rise of the Angiosperms.” Nature, vol. 629, Apr. 2024, pp. 1–8, https://doi.org/10.1038/s41586-024-07324-0.

Research output mentioned “polysaccharide” in title, abstract or keywords.

Zhang, Quanwei, et al. “M Cells of Mouse and Human Peyer’s Patches Mediate the Lymphatic Absorption of an Astragalus Hyperbranched Heteroglycan.” Carbohydrate Polymers, vol. 296, Elsevier BV, Nov. 2022, pp. 119952–52, https://doi.org/10.1016/j.carbpol.2022.119952.

Cheng, Chung-wah, et al. “CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration.” Annals of Internal Medicine, vol. 167, no. 2, May 2017, p. 112, https://doi.org/10.7326/m16-2977.

Cheng, Chung-wah, et al. “Extending the CONSORT Statement to Moxibustion.” Journal of Integrative Medicine, vol. 11, no. 1, Jan. 2013, pp. 54–63, https://doi.org/10.3736/jintegrmed2013009.

Zhang, Xuan, et al. “STandards for Reporting Interventions in Clinical Trials of Tuina/Massage (STRICTOTM): Extending the CONSORT Statement.” Journal of Evidence-Based Medicine, vol. 16, no. 1, Wiley-Blackwell, Mar. 2023, pp. 68–81, https://doi.org/10.1111/jebm.12522.